Hydrocortisone is Safe for Use During Pregnancy
Hydrocortisone is the preferred glucocorticoid for use during pregnancy and is considered safe, particularly when used at appropriate doses. 1
Key Recommendations from Guidelines
The Endocrine Society Clinical Practice Guideline explicitly recommends hydrocortisone as the glucocorticoid of choice in pregnant women, specifically stating that hydrocortisone should be used over cortisone acetate, prednisolone, or prednisone, and strongly recommends against dexamethasone because it is not inactivated in the placenta 1. This distinction is critical—hydrocortisone is metabolized by placental enzymes, limiting fetal exposure, whereas dexamethasone crosses freely and can affect fetal development.
Safety Profile
No Major Birth Defects
The 2025 EULAR guidelines confirm that prednisone and prednisolone (which are metabolized to similar active compounds as hydrocortisone) are not associated with an increased rate of major birth defects 2. While earlier studies suggested a possible association between systemic corticosteroids and oral clefts, more recent evidence has not replicated these findings 3.
Dose-Dependent Considerations
Safety is dose-dependent. The EULAR guidelines note that:
- Daily doses ≤5 mg are associated with low risk 2
- Higher doses over prolonged periods may increase risks of pregnancy-associated osteoporosis, gestational diabetes, serious maternal infections, and preterm birth 2
- However, these risks must be weighed against the danger of uncontrolled maternal disease
Specific Pregnancy Use
For pregnant women with primary adrenal insufficiency (PAI), hydrocortisone is the standard treatment. Doses should be increased by 20-40% from the 24th week onward to reflect physiological increases in free cortisol during pregnancy 1. During active labor, stress dosing similar to major surgical stress is recommended 1.
Clinical Evidence
A prospective study of 204 women exposed to hydrocortisone-pramoxine (Proctofoam-HC) in the third trimester found no adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications 4.
Important Caveats
Neonatal Monitoring
The FDA label notes that infants born to mothers who received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism 5. This is a manageable risk with appropriate neonatal monitoring.
Disease Control Priority
The key principle is that uncontrolled maternal disease poses greater risks to both mother and fetus than appropriate corticosteroid therapy. The benefits of disease control typically outweigh the potential risks of hydrocortisone use 2.
Avoid Long-Acting Alternatives
Never use dexamethasone in pregnancy unless treating specific fetal conditions, as it crosses the placenta freely and can cause lasting epigenetic changes 1, 6.
Practical Approach
- Use hydrocortisone as the first-line glucocorticoid in pregnancy
- Aim for the lowest effective dose, ideally ≤5 mg/day equivalent when possible
- Monitor for gestational diabetes, hypertension, and infection
- Increase dose in third trimester if treating adrenal insufficiency
- Plan for stress dosing during labor
- Arrange neonatal monitoring if substantial doses were used